Abstract：Objective To express the antibody Hu5F9 against cluster of differentiation 47 (CD47) in CHO-S cells, then purify and identify the expressed product. Methods The recombinant plasmid containing the genes encoding the light and heavy chains of Hu5F9 was transfected into CHO-S cells for expression. After the cell supernatant were collected for detection, the target antibody was purified and identified by humanized Fc-tag. Results The construction of Hu5F9 vector was verified by double-enzyme digestion and gene sequencing. The cell supernatant was detected by SDS-PAGE, and the antibody light chain, heavy chain and complete antibody bands were visible. After antibody purification, the Western blot identification results showed that the band size was consistent with the expectation. Conclusion Anti-CD47 antibody Hu5F9 was successfully expressed in CHO-S cells, which provided a research basis for subsequent drug research and development.
范蓓； 张静静； 邢体坤； 刘伟； 王斌； 宋路萍； 安文琪. 抗CD47抗体Hu5F9真核表达载体构建与表达[J]. 中国当代医药, 2022, 29(21): 5-8转13.
FAN Bei； ZHANG Jingjing； XING Tikun； LIU Wei； WANG Bin； SONG Luping； AN Wenqi. Construction and expression of anti-CD47 antibody Hu5F9 eukaryotic expression vector. 中国当代医药, 2022, 29(21): 5-8转13.
Sikic BI，Lakhani N，Patnaik A，et al.First-in-Human，First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers[J].J Clin Oncol，2019，37（12）：946-953.
[3]
Zhang M，Hutter G，Kahn SA，et al.Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo[J].PLoS One，2016，11（4）：e0153550.
Liu J，Wang L，Zhao F，et al.Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential[J].PLoS One，2015，10（9）：e0137345.
[6]
Donini R，Haslam SM，Kontoravdi C.Glycoengineering Chinese hamster ovary cells：a short history[J].Biochem Soc Trans，2021，49（2）：915-931.
[7]
Guo X，Wang C，Wang TY.Chromatin-modifying elements for recombinant protein production in mammalian cell systems[J].Crit Rev Biotechnol，2020，40（7）：1035-1043.
Sharker SM，Rahman A.A Review on the Current Methods of Chinese Hamster Ovary （CHO） Cells Cultivation for the Production of Therapeutic Protein[J].Curr Drug Discov Technol，2021，18（3）：354-364.
Russ A，Hua AB，Montfort WR，et al.Blocking "don′t eat me" signal of CD47-SIRPα in hematological malignancies，an in-depth review[J].Blood Rev，2018，32（6）：480-489.
[14]
于晓妍.抗CD47治疗性抗体候选分子成药性评价[D].北京：军事科学院，2019.
[15]
Advani R，Flinn I，Popplewell L，et al.CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin′s Lymphoma[J].N Engl J Med，2018，379（18）：1711-1721.
[16]
Upton R，Banuelos A，Feng D，et al.Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance[J].Proc Natl Acad Sci U S A，2021，118（29）：e2026849118.
[17]
Ansell SM，Maris MB，Lesokhin AM，et al.Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies[J].Clin Cancer Res，2021，27（8）：2190-2199.
[18]
Weiskopf K，Ring AM，Ho CC，et al.Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies[J].Science，2013，341（6141）：88-91.
[19]
Lu QS，Chen X，Wang S，et al.Potential New Cancer Immunotherapy：Anti-CD47-SIRPα Antibodies[J].Onco Targets Ther，2020，13：9323-9331.
[20]
Brierley CK，Staves J，Roberts C，et al.The effects of monoclonal anti-CD47 on RBCs，compatibility testing，and transfusion requirements in refractory acute myeloid leukemia[J].Transfusion，2019，59（7）：2248-2254.
[21]
Velliquette RW，Aeschlimann J，Kirkegaard J，et al.Monoclonal anti-CD47 interference in red cell and platelet testing[J].Transfusion，2019，59（2）：730-737.
[22]
Yu XY，Qiu WY，Long F，et al.A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety[J].Biochimie，2018，151：54-66.
京公网安备 11010502046607号